Literature DB >> 24059400

Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI.

Andrew B Rosenkrantz1, Ruth P Lim, Mershad Haghighi, Molly B Somberg, James S Babb, Samir S Taneja.   

Abstract

OBJECTIVE: The objective of our study was to compare interreader reproducibility of the recently proposed "Prostate Imaging Reporting and Data System," or "PI-RADS," scale incorporating fixed criteria and a standard Likert scale based on overall impression for prostate cancer localization using multiparametric MRI.
MATERIALS AND METHODS: Fifty-five patients who underwent a 3-T prostate MRI examination using a pelvic phased-array coil and incorporating T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging were included in the study. Three radiologists (6, 4, and 1 year of experience) independently scored 18 regions (12 in the peripheral zone [PZ] and six in the transition zone [TZ]) using PI-RADS (range, 3-15) and Likert (range, 1-5) scales, which were based on fixed criteria and overall impression, respectively. Interreader reproducibility was evaluated using the concordance correlation coefficient (CCC), which assesses exact agreement between scores (minimal, < 0.2; poor, 0.2-<0.4; moderate, 0.4-<0.6; strong, 0.6-<0.8; almost perfect, ≥ 0.8).
RESULTS: Agreement between experienced readers was strong in the PZ and TZ combined and in the PZ for both the PI-RADS and Likert scales (CCC = 0.608-0.677), moderate in the TZ for the Likert scale (CCC = 0.519), and poor in the TZ for PI-RADS (CCC = 0.376). Agreement between experienced and inexperienced readers was moderate to poor in the PZ and TZ combined for PI-RADS (CCC = 0.340-0.477), moderate in the PZ and TZ combined for the Likert scale (CCC = 0.471-0.497), moderate in the PZ for PI-RADS and Likert scales (CCC = 0.472-0.542), minimal to poor in the TZ for PI-RADS (CCC = 0.094-0.283), and poor in the TZ for the Likert scale (CCC = 0.287-0.400).
CONCLUSION: Interreader reproducibility tended to be higher for relatively experienced readers than for less experienced readers and to be higher in the PZ than in the TZ. For the relatively experienced readers, reproducibility was similar for PI-RADS and Likert scales in the PZ but was somewhat higher for the Likert scale than for PI-RADS in the TZ.

Entities:  

Mesh:

Year:  2013        PMID: 24059400     DOI: 10.2214/AJR.12.10173

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  60 in total

1.  Intra- and interreader reproducibility of PI-RADSv2: A multireader study.

Authors:  Clayton P Smith; Stephanie A Harmon; Tristan Barrett; Leonardo K Bittencourt; Yan Mee Law; Haytham Shebel; Julie Y An; Marcin Czarniecki; Sherif Mehralivand; Mehmet Coskun; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2018-12-21       Impact factor: 4.813

2.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

3.  The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Authors:  Pedro Recabal; Melissa Assel; Daniel D Sjoberg; Daniel Lee; Vincent P Laudone; Karim Touijer; James A Eastham; Hebert A Vargas; Jonathan Coleman; Behfar Ehdaie
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

4.  Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Hedvig Hricak; Evis Sala; Junting Zheng; Chaya S Moskowitz; Melanie Bernstein; James A Eastham; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2014-08-07       Impact factor: 5.315

5.  Detection of Clinically Significant Prostate Cancer: Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging-A Multireader Study.

Authors:  Borna K Barth; Pieter J L De Visschere; Alexander Cornelius; Carlos Nicolau; Hebert Alberto Vargas; Daniel Eberli; Olivio F Donati
Journal:  Radiology       Date:  2017-03-27       Impact factor: 11.105

6.  Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists.

Authors:  Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis
Journal:  Radiology       Date:  2016-04-01       Impact factor: 11.105

7.  High-resolution whole-brain DCE-MRI using constrained reconstruction: Prospective clinical evaluation in brain tumor patients.

Authors:  Yi Guo; R Marc Lebel; Yinghua Zhu; Sajan Goud Lingala; Mark S Shiroishi; Meng Law; Krishna Nayak
Journal:  Med Phys       Date:  2016-05       Impact factor: 4.071

8.  Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?

Authors:  Paolo Capogrosso; Emily A Vertosick; Nicole E Benfante; Daniel D Sjoberg; Andrew J Vickers; James A Eastham
Journal:  Clin Genitourin Cancer       Date:  2019-05-16       Impact factor: 2.872

Review 9.  PI-RADS v2: Current standing and future outlook.

Authors:  Clayton P Smith; Barış Türkbey
Journal:  Turk J Urol       Date:  2018-05-01

10.  Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.

Authors:  Daniel Junker; Michael Quentin; Udo Nagele; Michael Edlinger; Jonathan Richenberg; Georg Schaefer; Michael Ladurner; Werner Jaschke; Wolfgang Horninger; Friedrich Aigner
Journal:  World J Urol       Date:  2014-08-01       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.